营收大涨142%,云顶新耀剑指2030年150亿元营收

21世纪经济报道
Mar 30

2025年是“十四五”规划的收官之年,也是中国生物医药行业迈入高质量发展的关键分水岭。得益于多年积累并持续涌现的创新成果、不断加速的研发进展及深化的全球合作,一批具备核心竞争力的创新药企业脱颖而出,云顶新耀(01952.HK)便是其中的典型代表。  日前,云顶新耀披露2025年业绩报告显示,全年实现总收入17.07亿元,同比大幅增长142%。报告期内,公司运营费用占收入比重同比下降90.1个百分点...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10